Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Rating) gapped down prior to trading on Tuesday . The stock had previously closed at $13.85, but opened at $13.48. Voyager Therapeutics shares last traded at $12.38, with a volume of 283,651 shares changing hands.
Analyst Upgrades and Downgrades
VYGR has been the topic of several recent research reports. TheStreet raised shares of Voyager Therapeutics from a “d” rating to a “c+” rating in a report on Friday, May 19th. Truist Financial initiated coverage on shares of Voyager Therapeutics in a report on Wednesday, May 10th. They issued a “buy” rating and a $18.00 price target on the stock. Oppenheimer assumed coverage on Voyager Therapeutics in a research report on Thursday, March 9th. They set an “outperform” rating and a $14.00 price target on the stock. Finally, StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, May 11th.
Voyager Therapeutics Stock Performance
The firm’s 50 day moving average is $8.66 and its 200-day moving average is $7.60. The stock has a market capitalization of $569.94 million, a price-to-earnings ratio of 5.74 and a beta of 1.12.
Insiders Place Their Bets
In other news, VP Robert W. Hesslein sold 4,410 shares of the business’s stock in a transaction that occurred on Monday, March 20th. The stock was sold at an average price of $7.76, for a total value of $34,221.60. Following the completion of the sale, the vice president now directly owns 102,200 shares in the company, valued at $793,072. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Voyager Therapeutics news, CEO Alfred Sandrock sold 7,437 shares of the stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $7.83, for a total transaction of $58,231.71. Following the transaction, the chief executive officer now directly owns 214,618 shares of the company’s stock, valued at $1,680,458.94. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Robert W. Hesslein sold 4,410 shares of Voyager Therapeutics stock in a transaction dated Monday, March 20th. The shares were sold at an average price of $7.76, for a total transaction of $34,221.60. Following the completion of the sale, the vice president now owns 102,200 shares in the company, valued at approximately $793,072. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,953 shares of company stock worth $147,684. 22.00% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of VYGR. Citigroup Inc. purchased a new stake in Voyager Therapeutics during the 1st quarter worth approximately $186,000. BlackRock Inc. increased its position in shares of Voyager Therapeutics by 10.6% during the first quarter. BlackRock Inc. now owns 514,155 shares of the company’s stock worth $3,919,000 after purchasing an additional 49,319 shares in the last quarter. Lazard Asset Management LLC raised its stake in Voyager Therapeutics by 144.7% in the 1st quarter. Lazard Asset Management LLC now owns 17,678 shares of the company’s stock valued at $134,000 after purchasing an additional 10,455 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new position in Voyager Therapeutics in the 1st quarter valued at $122,000. Finally, Northern Trust Corp boosted its stake in Voyager Therapeutics by 2.2% during the 1st quarter. Northern Trust Corp now owns 79,119 shares of the company’s stock worth $603,000 after purchasing an additional 1,683 shares during the last quarter. 59.58% of the stock is owned by hedge funds and other institutional investors.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A.
- Get a free copy of the StockNews.com research report on Voyager Therapeutics (VYGR)
- Toll Brothers Rises On Results, But The Roof Is In Place
- It’s Time To Try On VF Corporation’s 6% Yield
- PetCo Management Getting it Right? Earnings Beat Says Yes
- Axcelis Stock In Buy Range After Chart Breakout, Strong Guidance
- Kohl’s 10% Yield Comes Into High Fashion
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.